Menu

Physician Editorial

About Physician Editorial

http://physicianeditorial.com

Posts by Physician Editorial:

Sanofi and Regeneron Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016

, , , ,

ODYSSEY ESCAPE data concurrently published in the European Heart Journal Paris, France and Tarrytown, New York – August 29, 2016 – Sanofi and Regeneron Pharmaceuticals, Inc. today announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous […]

Mylan to Launch First Generic to EpiPen® Auto-Injector at a List Price of $300 per Two-Pack Carton, a More than 50% Discount to the Brand Product

, , ,

HERTFORDSHIRE, England and PITTSBURGH, Aug. 29, 2016 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL) today announced that its U.S. subsidiary will launch the first generic to EpiPen® Auto-Injector (epinephrine injection, USP) at a list price of $300 per generic EpiPen® two-pack carton, which represents a discount of more than 50% to the Mylan list price, […]

Pfizer To Acquire Small Molecule Anti-Infective Business From AstraZeneca

, , ,

Strong fit with Pfizer’s existing anti-infective portfolio Pfizer’s focus on infectious disease and expertise in this category will help enable broader access to anti-infective portfolio Expected to enhance near-term revenue growth potential for Pfizer’s Essential Health business August 24, 2016 – Pfizer Inc. (NYSE:PFE) today announced that it has entered into an agreement with AstraZeneca […]

Pfizer To Acquire Medivation

, , , ,

Propels Pfizer into a leading position in oncology Medivation agrees to transaction valued at $81.50 per Medivation share in cash, for a total enterprise value of approximately $14 billion Expected to be immediately accretive to Pfizer’s Adjusted Diluted EPS upon closing, approximately $0.05 accretive in first full year after close with additional accretion and growth […]

Bayer and CRISPR Therapeutics joint venture, named Casebia Therapeutics, establishes operations in Cambridge, MA

, , , ,

Transaction formally closed in the first quarter of 2016 / Laboratory and office space will be near Kendall Square in Cambridge, MA / Hiring is underway and efforts have begun on initial programs in hematology and ophthalmology Leverkusen, Germany and Basel, Switzerland, August 19, 2016 – Casebia Therapeutics, the joint venture founded by Bayer and […]

FDA Approves TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain

, ,

August 19, 2016 – Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules, for oral use, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. TROXYCA […]

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

, , , ,

August 8, 2016 KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, at a fixed dose of 200 mg every three weeks, for the treatment of patients with recurrent or […]

Results from Merck’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine

, , , ,

August 8, 2016 KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR . C-EDGE CO-STAR is a Phase 3 trial evaluating the use of ZEPATIER™ (elbasvir and grazoprevir) 50mg/100mg tablets in patients with chronic hepatitis C (HCV) genotype (GT) 1, […]

Bristol-Myers Squibb Statement on Top-Line Results from CheckMate – 026

, , , ,

August 5, 2016 – While the news regarding CheckMate – 026 is disappointing, Bristol-Myers Squibb is proud of all that the company has and aims to accomplish with Opdivo. We are indeed transforming cancer care, and remain committed to bringing the benefit of our medicines to the greatest number of patients across multiple cancers. We […]

Mylan Completes Acquisition of Meda

, ,

HERTFORDSHIRE, England and PITTSBURGH, Aug. 5, 2016 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has completed the settlement of its recommended public offer to the shareholders of Meda Aktiebolag (publ.) to tender all their shares in Meda to Mylan (the “Offer”). As previously announced, the Offer was accepted by shareholders holding […]

«‹ 60 61 62 63›»